Séguin C, Cusan L, Bélanger A, Kelly P A, Labrie F, Raynaud J P
Mol Cell Endocrinol. 1981 Jan;21(1):37-41. doi: 10.1016/0303-7207(81)90028-9.
Combined treatment of adult male rats with the LHRH agonist, [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide, and a non-steroid antiandrogen, RU 23908, led to a rapid and marked atrophy of the ventral prostate and seminal vesicles. Treatment with the LHRH agonist decreased androgen secretion and thus facilitated the action of the antiandrogen in androgen-dependent tissues. Such a combined treatment could be useful in the treatment of androgen-dependent pathologies in man, particularly in prostatic adenocarcinoma and possibly benign prostatic hyperplasia.